Skip to main content
TipRanks
Go Ultimate75% OFF

BioNano Genomics (0A4K) Stock Statistics & Valuation Metrics

13 Followers

Total Valuation

BioNano Genomics has a market cap or net worth of $13.31M. The enterprise value is $16.58M.

Market Cap
$13.31M
Enterprise Value
$16.58M

Share Statistics

BioNano Genomics has 13,979,584 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
13,979,584
Owned by Insiders
0.96%
Owned by Institutions
11.53%

Financial Efficiency

BioNano Genomics’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -64.63%.

Return on Equity (ROE)
-0.59
Return on Assets (ROA)
-0.36
Return on Invested Capital (ROIC)
-64.63%
Return on Capital Employed (ROCE)
-0.66
Revenue Per Employee
296.96K
Profits Per Employee
-274.95K
Employee Count
96
Asset Turnover
0.39
Inventory Turnover
4.08

Valuation Ratios

The current PE Ratio of BioNano Genomics is -0.36. BioNano Genomics’s PEG ratio is -0.00.

PE Ratio
-0.36
PS Ratio
0.43
PB Ratio
0.41
Price to FCF
-0.70
Price to Operating Cash Flow
-0.60
PEG Ratio
-0.00

Income Statement

In the last 12 months, BioNano Genomics had revenue of 28.51M and earned -26.39M in profits. Earnings per share was -4.85.

Revenue
28.51M
Gross Profit
6.26M
Operating Income
-33.34M
Pretax Income
-26.33M
Net Income
-26.39M
EBITDA
-16.30M
Earnings Per Share (EPS)
-4.85

Cash Flow

In the last 12 months, operating cash flow was -19.09M and capital expenditures 0, giving a free cash flow of -19.09M billion.

Operating Cash Flow
-19.09M
Free Cash Flow
-19.09M
Free Cash Flow per Share
-1.59

Dividends & Yields

BioNano Genomics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-142.54%
Earnings Yield
-262.19%

Stock Price Statistics

Beta
0.66
52-Week Price Change
0.00%
50-Day Moving Average
5.25
200-Day Moving Average
5.25
Relative Strength Index (RSI)
―
Average Volume (3m)
―

Important Dates

BioNano Genomics upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 10, 2026
Next Earnings Date
Mar 10, 2027
Ex-Dividend Date
―

Financial Position

BioNano Genomics as a current ratio of 1.98, with Debt / Equity ratio of 15.57%

Current Ratio
1.98
Quick Ratio
1.74
Debt to Market Cap
0.72
Net Debt to EBITDA
-0.24
Interest Coverage Ratio
-111.88

Taxes

In the past 12 months, BioNano Genomics has paid 67.00K in taxes.

Income Tax
67.00K
Effective Tax Rate
-0.00

Enterprise Valuation

BioNano Genomics EV to EBITDA ratio is -0.68, with an EV/FCF ratio of -0.82.

EV to Sales
0.50
EV to EBITDA
-0.68
EV to Free Cash Flow
-0.82
EV to Operating Cash Flow
-0.82

Balance Sheet

BioNano Genomics has $4.36M in cash and marketable securities with $6.54M in debt, giving a net cash position of -$2.19M billion.

Cash & Marketable Securities
$4.36M
Total Debt
$6.54M
Net Cash
-$2.19M
Net Cash Per Share
-$0.16
Tangible Book Value Per Share
$2.33

Margins

Gross margin is 47.98%, with operating margin of -97.11%, and net profit margin of -96.87%.

Gross Margin
47.98%
Operating Margin
-97.11%
Pretax Margin
-96.68%
Net Profit Margin
-96.87%
EBITDA Margin
-73.34%
EBIT Margin
-96.00%

Analyst Forecast

The average price target for BioNano Genomics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$4.00
Price Target Upside
23.87% Downside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
8.23%
EPS Growth Forecast
82.76%